Product Description
| Brand |
Medtronic |
| Stent Diameter (mm) |
2.75 |
| Stent Length (mm) |
08, 14, 22, 26 & 30 |
| CAT No |
RSINT27508X, RSINT27514X, RSINT27522X, RSINT27526X & RSINT27530X |
| Catheter Length |
300 cm |
Resolute Integrity is a drug-eluting stent (DES) and balloon catheter that offers excellent deliverability and flexibility for percutaneous coronary interventions.
Continuous Sinusoidal Design for Flexibility and DeliverabilityThe unique continuous sinusoidal, single-wire construction of the Resolute Integrity stent enhances its flexibility and conformability, allowing for precise navigation and placement even in complex coronary anatomies. This innovative design reduces the risk of vessel trauma during percutaneous coronary intervention (PCI) and improves deliverability through tortuous vessels, ensuring effective treatment of de novo lesions.
Controlled Zotarolimus Drug Elution Reduces RestenosisWith advanced zotarolimus drug coating, the stent delivers a controlled and sustained release of the pharmaceutical agent directly to the vessel wall. This targeted approach minimizes the potential for restenosis, a common post-angioplasty complication, and supports long-term vessel patency. The technology is specifically developed for optimal drug diffusion and patient outcomes.
Superior Visualization and Professional CompatibilityRadiopacity is a standout feature of the Resolute Integrity DES, ensuring that clinicians have excellent fluoroscopic visibility during navigation and deployment. Compatibility with standard balloon angioplasty catheters and 6F guide catheters facilitates integration with existing procedural workflows, while its rapid-exchange delivery system streamlines use in interventional cardiology settings.
FAQ's of Medtronic Resolute Integrity DES Drug-eluting Stent (SD 2.75):
Q: How is the Medtronic Resolute Integrity DES implanted during a coronary intervention?
A: The stent is delivered via a rapid-exchange system compatible with standard balloon angioplasty catheters. Once positioned at the site of the de novo coronary lesion, the stent is expanded and deployed using the balloon, maintaining vessel patency while releasing zotarolimus to limit restenosis.
Q: What are the primary clinical benefits of using the Resolute Integrity DES?
A: The use of zotarolimus-eluting technology reduces restenosis by delivering a controlled dose of medication directly to the vessel wall. The continuous sinusoidal design enhances flexibility and deliverability, lowering the risk of vessel trauma and enabling successful treatment of complex vascular anatomies.
Q: When should the Resolute Integrity DES be considered for patient treatment?
A: This drug-eluting stent is indicated for the treatment of de novo lesions in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI). It should be used when maintaining vessel patency and minimizing restenosis risk are critical goals.
Q: Where is the expiration date for the stent found, and how should it be stored?
A: The expiration date is clearly printed on the packaging. The stent should be stored in its original, sterile packaging, kept dry, and protected from extreme temperatures to maintain sterility and product integrity.
Q: What stent lengths are available and what is the measurement range for this device?
A: The Resolute Integrity DES is available in a range of lengths-such as 8, 12, 15, 18, 24, 30, and 38 mm-with a fixed stent diameter of 2.75 mm. This allows for precise matching to lesion length during coronary procedures.
Q: How does the stent's radiopacity enhance procedural outcomes?
A: Its excellent radiopacity provides clear fluoroscopic visualization, allowing clinicians to accurately track, position, and deploy the stent, which is particularly valuable during challenging or complex interventions.